Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serologic Assay Validation of HIL-214 in Adults
NCT05972733Phase 2Completed
- Sponsor
- HilleVax
- Start
- Aug 2023
- Primary completion
- Aug 2023
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of NoV GI.1/GII.4 bivalent VLP vaccine in norovirus gastroenteritis, sponsored by HilleVax. Started Aug 2023; status: completed.
02
Drugs
NoV GI.1/GII.4 bivalent VLP vaccine
03
Conditions
norovirus gastroenteritis
Beyond the preview
Go deeper on NCT05972733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972733.